Atara Biotherapeutics

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Atara Biotherapeutics strengthens financial position and advances clinical milestones

Atara Biotherapeutics is strategically positioned to drive growth through financial stability, pipeline advancements, and operational efficiency.
Despite workforce reductions, the company's focus on key clinical milestones and regulatory milestones bodes well for future revenue potential.
Navigating challenges in workforce restructuring and regulatory hurdles, Atara remains focused on leveraging opportunities in CAR-T therapies and autoimmune diseases.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Investors need to pay close attention to Atara (ATRA) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Atara (ATRA) Stock?

Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q2 2019 Results - Earnings Call Transcript

SRC Energy

The following companies are considered "falling knives" because their share prices have tumbled more than 59% over the past year through Aug.

Analysts Recommend These 2 Falling Knives (Aug 5)

Atara recently published excellent tolerability data for ATA-188 at the 5th Congress of the European Academy of Neurology (EAN) in Oslo, Norway.

Atara: The Silver Bullet For Multiple Sclerosis

AvroBio Inc

Melinta Therapeutics

Tuesday was a breakout day for a few biotech companies that saw solid gains. With the markets at all-time highs, these companies could help push things higher.

Tuesday’s Biggest Biotech Movers (July 16)

bluebird bio

Genprex

Hemispherx Biopharma

Incyte

As our understanding of how cancer works evolves, so too are the methods that we are taking to treat the condition.

5 Immunotherapy Stocks to Keep a Close Eye On

Atara's shares have collapsed this year. Here's why.

Why Atara Biotherapeutics Has Slumped in 2019

Atara (ATRA) announces initial ATA188 phase I safety results for patients with progressive MS.

Atara Reports Initial Data for Multiple Sclerosis Candidate

The shares of Atara Biotherapeutics have had a volatile ride since the company came public late in 2014.

Atara Biotherapeutics: What Lies Ahead

ATRA is a leading developer of T-Cell therapies and has its lead candidate targeting a rare disease.

Atara Biotherapeutics: T-Cell Therapy Developer With Late-Stage Candidate In Rare Disease

Atara Biotherapeutics, Inc. (ATRA) CEO Isaac Ciechanover on Q1 2019 Results - Earnings Call Transcript

Investors are growing impatient with this clinical-stage biotech.

Why Atara Biotherapeutics Stock Is Imploding Today

CRISPR Therapeutics

Gilead Sciences

Novartis

Atara Biotherapeutics and Crispr Therapeutics stand out as strong takeover candidates. Here's why.

2 Best Biotech Buyout Plays

News for Atara Biotherapeutics Stock (ATRA)